Tag: targeted therapy
-
Hutchmed Wins Priority NDA Acceptance in China for Savolitinib After Positive Phase II Data
Overview: Hutchmed Moves Forward with Savolitinib in China Hutchmed (Hydrogenated Medicine) has announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Savolitinib with priority review. This milestone follows a sequence of supportive data, including a positive Phase II registration study conducted in Chinese patients and a 2023 Breakthrough…
-
Study Uncovers Therapeutic Vulnerability in Aggressive Subtype of Triple-Negative Breast Cancer
Groundbreaking finding in a difficult cancer subtype A new study published in Science Translational Medicine from researchers at The University of Texas MD Anderson Cancer Center identifies a previously unrecognized therapeutic vulnerability in an aggressive subtype of triple-negative breast cancer (TNBC). The work, led by Dr. Khan and a multidisciplinary team, focuses on molecular drivers…
-
Therapeutic Vulnerability Uncovered in Aggressive Triple-Negative Breast Cancer Subtype
Breakthrough in Aggressive TNBC Subtype A landmark study published in Science Translational Medicine reveals a previously unrecognized therapeutic vulnerability in an aggressive subtype of triple-negative breast cancer (TNBC). Conducted by researchers at The University of Texas MD Anderson Cancer Center, the work provides new insight into how this hard-to-treat cancer might be targeted more effectively…
-
Decoding Neoschaftoside: Systems Biology Insights for Targeting Lung Cancer from Ailanthus altissima
Introduction: The promise of plant-derived compounds in lung cancer therapy Lung cancer remains a leading cause of cancer mortality worldwide, with rising incidence and significant heterogeneity in tumor biology. In parallel, natural products from medicinal plants are increasingly explored for novel anticancer effects. Neoschaftoside, a flavonoid glycoside isolated from Ailanthus altissima, has attracted scientific interest…
-
Bezuclastinib Peaks in GIST: Positive PEAK Phase 3 Results for KIT Exon 17/18 Mutants
New Phase 3 data positions Bezuclastinib as a potential new standard for KIT Exon 17/18 mutant GIST In a pivotal development for patients with advanced gastrointestinal stromal tumors (GISTs), Bezuclastinib demonstrated positive outcomes in the PEAK Phase 3 study focusing on KIT exon 17/18 mutant disease. GISTs are driven by complex mutations in the KIT…
-
Bezuclastinib Achieves Positive PEAK Phase 3 Results in Advanced GIST: A Potential New Standard for KIT Exon 17/18 Mutant Disease
Bezuclastinib Makes a Major Leap in KIT Exon 17/18 Mutant GIST Recent PEAK Phase 3 results are positioning Bezuclinib as a potentially practice-changing therapy for patients with advanced gastrointestinal stromal tumors (GIST) driven by KIT Exon 17/18 mutations. These mutations have long been associated with primary resistance to first-line therapies and later-line inhibitors, making the…
-
Bezuclastinib PEAK Phase 3: A Potential New Standard for KIT Exon 17/18 GIST
Bezuclastinib Hits Positive PEAK Phase 3 Results in Advanced GIST Gastrointestinal stromal tumors (GIST) have long been driven by KIT mutations, with targeted therapies reshaping patient outcomes over the past two decades. The emergence of resistance, particularly in those with KIT Exon 17 and Exon 18 mutations, has remained a persistent challenge. Bezuclastinib’s latest PEAK…
-
IFITM3-MET Interaction Drives Osimertinib Resistance in EGFR-Mutant NSCLC
Overview: A New Mechanism Behind Osimertinib Resistance in EGFR-Mutant NSCLC Osimertinib has transformed the treatment landscape for patients with EGFR-mutant non-small cell lung cancer (NSCLC). Yet resistance remains a major hurdle. A recent study identifies a non-genetic mechanism: the membrane protein IFITM3 interacts with MET to activate the PI3K-AKT signaling axis, enabling tumor cells to…
-
MAEA Protein’s New Role Could Boost Chemotherapy Response
New findings reveal MAEA’s unexpected function in DNA repair and cancer therapy A University of Alberta research team has uncovered a surprising new role for the MAEA protein, historically associated with red blood cell development and linked to developmental disorders. In a study published in Science Advances, the researchers show that MAEA also helps control…
-
Blocking PDIA1 and PDIA5: A New Strategy to Weaken Prostate Tumors and Boost Drug Effectiveness
New vulnerability in prostate cancer identified: two enzymes that protect the androgen receptor A major international study has uncovered a promising vulnerability in prostate cancer cells that could improve treatment for one of the most common cancers in men. Published in the Proceedings of the National Academy of Sciences (PNAS), the research shows that two…